title: Treatment of metastatic renal cell carcinoma with activated autologous macrophages and granulocyte--macrophage colony-stimulating factor.
abstract: Fifteen patients with progressive metastatic renal cell carcinoma were treated with granulocyte-macrophage colony-stimulating factor and intravenous infusions of activated autologous macrophages (AAMs). The latter were prepared from leukapheresis-separated mononuclear cells cultured in the presence of granulocyte-macrophage colony-stimulating factor, exposed to gamma interferon, and submitted to elutriation to separate AAMs. Three intravenous injections of AAMs were performed within a 2-week interval. This treatment cycle was repeated once or twice, in cases of tumor response or stabilization. Ninety-seven preparations containing a mean 3 x 10(9) AAMs were administered and usually well tolerated. One partial response, eight stabilizations and six progressions were observed. The median time to progression and median overall survival time after inclusion were 7 and 9 months, respectively. The cells injected did not accumulate substantially in tumor lesions, as shown by scintigraphic imaging of indium-111-labeled AAMs. Thus, combined granulocyte-macrophage colony-stimulating factor and AAM treatment was well tolerated and resulted in transitory stabilization (n = 8) or partial regression (n = 1) in 9 of 15 patients.
authors.affiliation: Centre Régional de Lutte Contre le Cancer Eugène Marquis, Rennes, France.
authors.forename: T
authors.initials: T
authors.lastname: Lesimple
authors.forename: A
authors.initials: A
authors.lastname: Moisan
authors.forename: F
authors.initials: F
authors.lastname: Guillé
authors.forename: C
authors.initials: C
authors.lastname: Leberre
authors.forename: R
authors.initials: R
authors.lastname: Audran
authors.forename: B
authors.initials: B
authors.lastname: Drenou
authors.forename: L
authors.initials: L
authors.lastname: Toujas
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D002478:Cells, Cultured; D003131:Combined Modality Therapy; D016207:Cytokines / Q000096:biosynthesis; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000009:adverse effects; D007205:Indium Radioisotopes / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D008262:Macrophage Activation; D008264:Macrophages / Q000276:immunology / Q000637:transplantation*; D009362:Neoplasm Metastasis; D014182:Transplantation, Autologous
chemical_list: D000276:Adjuvants, Immunologic; D016207:Cytokines; D007205:Indium Radioisotopes; D016178:Granulocyte-Macrophage Colony-Stimulating Factor